EGRX - イ―グル・ファ―マシュ―ティカルズ (Eagle Pharmaceuticals Inc.) イ―グル・ファ―マシュ―ティカルズ

 EGRXのチャート


 EGRXの企業情報

symbol EGRx
会社名 Eagle Pharmaceuticals Inc. (イ―グル・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 イーグル・ファーマスーティカルス(Eagle Pharmaceuticals Inc.)は専門の製薬会社。同社は救命救急診療と腫瘍分野での注射用製品の開発と製品化を行う。同社の製品ポートフォリオはアルガトロバン、Ryanodex、ドセタキセル注射剤、非アルコール製剤、ベンデカを含む。同社の上級候補製品はベンダムスチン抵抗値温度検出器(RTD)EP-3101、熱中症用のダントロレンナトリウム(EHS)EP-4104、薬物誘発性高体温用のダントロレンナトリウムEGL-4104-C-1702、ペメトレキセドEP-5101、フルベストラントEGL-5385-C-1701。同社の製品ポートフォリオはがん治療、救急医療、希少疾病に注目する。ベンダムスチンは、リツキシマブまたはリツキシマブ含有レジメンによる治療の6カ月または6カ月以内に進行した慢性リンパ球性白血病(CLL)および無痛性B細胞非ホジキンリンパ腫(NHL)に使用が認可されるアルキル化剤である。   イ―グル・ファ―マシュ―ティカルズは米国の特殊医薬品会社。米国食品医薬品局(FDA)の505(b)(2)による規制手順を活用して、主に救命救急及び腫瘍学分野の注射製剤の開発・商業化に重点を置く。先進的な製品には、悪性高熱症のための懸濁注射剤「Ryanodex」がある。本社はニュ―ジャ―ジ―州。   
本社所在地 50 Tice Boulevard Suite 315 Woodcliff Lake NJ 07677 USA
代表者氏名 Michael Graves マイケル・グレイブス
代表者役職名 Independent Chairman of the Board
電話番号 +1 201-326-5300
設立年月日 39083
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 108人
url www.eagleus.com
nasdaq_url https://www.nasdaq.com/symbol/egrx
adr_tso
EBITDA EBITDA(百万ドル) 59.09800
終値(lastsale) 63.42
時価総額(marketcap) 954846700.08
時価総額 時価総額(百万ドル) 948.07150
売上高 売上高(百万ドル) 215.72800
企業価値(EV) 企業価値(EV)(百万ドル) 894.54250
当期純利益 当期純利益(百万ドル) 33.19100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Eagle Pharmaceuticals Inc revenues decreased 17% to $105.9M. Net income decreased 81% to $5.3M. Revenues reflect License and other income decrease from $25M to $0K Royalty revenue decrease of 3% to $72M. Net income also reflects Research and development - Balancing val increase from $10.1M to $27.5M (expense) IE on Capital Financing Gross increase from $67K to $1.4M (expense).

 EGRXのテクニカル分析


 EGRXのニュース

   Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns  2021/01/11 11:50:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that, on January 8, 2021, the United States District Court for the District of Delaware postponed the January 11, 2021 vasopressin trial between Eagle and Endo Par Innovation Company, LLC, et al. due, in part, to ensure the health and safety of the trial teams in light of a COVID-19 concern. The trial is now scheduled to begin remotely starting February 1, 2021 and is exp
   Eagle Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference  2021/01/04 21:30:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference as follows: Date: Wednesday, January 13, 2021 Time: 4:30 p.m. Eastern Standard Time Webcast: https://jpmorgan.metameetings.net/events/healthcare21/sessions/35699-eagle-pharmaceuticals/webcast?gpu_only=true&kiosk=true
   Eagle Pharmaceuticals’ Presentation at Piper Sandler 32nd Annual Virtual Healthcare Conference Available for Viewing  2020/11/23 11:50:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company’s pre-recorded presentation at the Piper Sandler 32nd Annual Virtual Healthcare Conference is now available for viewing via the link below: https://pipersandler.zoom.us/rec/play/0TlXfXVGZ3QG7IgEE4PyzFEfiG8HyD57XqSaO9Uq1Rsb_J29jmyS2ZvqWskPC1MJPA_AP6kFUMjJQfFd.vyuNfKmJI0FvhIOg It is also available on the Company’s website at www.eagleus.com, under the Inves
   Eagle Pharmaceuticals Inc. (EGRX) Q3 2020 Earnings Call Transcript  2020/11/02 17:30:04 AlphaStreet
Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) Q3 2020 Earnings Call dated Nov. 02, 2020 Corporate Participants: Lisa M. Wilson — Investor Relations – In-Site Communications, Inc. Scott Tarriff — Founder, Chief Executive Officer and Director […]
   Earnings Scheduled For November 2, 2020  2020/11/02 12:55:36 Benzinga
Companies Reporting Before The Bell • Itron (NASDAQ: ITRI ) is likely to report quarterly earnings at $0.25 per share on revenue of $540.01 million. • AMC Networks (NASDAQ: AMCX ) is projected to report quarterly earnings at $1.28 per share on revenue of $606.04 million. • BWX Technologies (NYSE: BWXT ) is likely to report quarterly earnings at $0.68 per share on revenue of $499.24 million. • Clorox (NYSE: CLX ) is projected to report quarterly earnings at $2.32 per share on revenue of $1.75 billion. • Camping World Holdings (NYSE: CWH ) is estimated to report quarterly earnings at $0.96 per share on revenue of $1.51 billion. • Eagle Pharmaceuticals (NASDAQ: EGRX ) is likely to report quarterly earnings at $0.28 per share on revenue of $47.02 million. • Exterran (NYSE: EXTN ) is likely to report quarterly loss at $0.48 per share on revenue of $194.32 million. • FirstEnergy (NYSE: FE ) is likely to report quarterly earnings at $0.76 per share on revenue of $2.94 billion. • MGM Growth Properties (NYSE: MGP ) is expected to report quarterly earnings at $0.
   Eagle Pharmaceuticals’ Presentation at Piper Sandler 32nd Annual Virtual Healthcare Conference Available for Viewing  2020/11/23 11:50:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company’s pre-recorded presentation at the Piper Sandler 32nd Annual Virtual Healthcare Conference is now available for viewing via the link below: https://pipersandler.zoom.us/rec/play/0TlXfXVGZ3QG7IgEE4PyzFEfiG8HyD57XqSaO9Uq1Rsb_J29jmyS2ZvqWskPC1MJPA_AP6kFUMjJQfFd.vyuNfKmJI0FvhIOg It is also available on the Company’s website at www.eagleus.com, under the Inves
   Eagle Pharmaceuticals Inc. (EGRX) Q3 2020 Earnings Call Transcript  2020/11/02 17:30:04 AlphaStreet
Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) Q3 2020 Earnings Call dated Nov. 02, 2020 Corporate Participants: Lisa M. Wilson — Investor Relations – In-Site Communications, Inc. Scott Tarriff — Founder, Chief Executive Officer and Director […]
   Earnings Scheduled For November 2, 2020  2020/11/02 12:55:36 Benzinga
Companies Reporting Before The Bell • Itron (NASDAQ: ITRI ) is likely to report quarterly earnings at $0.25 per share on revenue of $540.01 million. • AMC Networks (NASDAQ: AMCX ) is projected to report quarterly earnings at $1.28 per share on revenue of $606.04 million. • BWX Technologies (NYSE: BWXT ) is likely to report quarterly earnings at $0.68 per share on revenue of $499.24 million. • Clorox (NYSE: CLX ) is projected to report quarterly earnings at $2.32 per share on revenue of $1.75 billion. • Camping World Holdings (NYSE: CWH ) is estimated to report quarterly earnings at $0.96 per share on revenue of $1.51 billion. • Eagle Pharmaceuticals (NASDAQ: EGRX ) is likely to report quarterly earnings at $0.28 per share on revenue of $47.02 million. • Exterran (NYSE: EXTN ) is likely to report quarterly loss at $0.48 per share on revenue of $194.32 million. • FirstEnergy (NYSE: FE ) is likely to report quarterly earnings at $0.76 per share on revenue of $2.94 billion. • MGM Growth Properties (NYSE: MGP ) is expected to report quarterly earnings at $0.
   Eagle Pharmaceuticals Reports Third Quarter 2020 Results  2020/11/02 11:47:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and nine months ended September 30, 2020. Business and Recent Highlights: Received formal notification from FDA granting Priority Review for the Company’s abbreviated new drug application (“ANDA”) filed for vasopressin. A trial date of January 11, 2021 has been set; Added four experienced pharmaceutical industry executives to clinical, form
   The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings  2020/11/01 14:40:39 Benzinga
Biotech stocks continued to sway to the tunes of the broader market in the week ended Oct. 30, which succumbed to geopolitical and macroeconomic concerns. Several big-name pharma companies, including Merck & Co. Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ), reported earnings during the week. The earnings news flow was broadly mixed. Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) was among the biggest decliners, as it halted a late-stage trial of its Duchenne muscular dystrophy drug. On the other hand, Scholar Rock Holding Corp. (NASDAQ: SRRK ) was up about over 175% during the week, reacting to positive mid-stage results for spinal muscular atrophy drug. On the COVID-19 front, Regeneron Pharmaceuticals Inc. said it is (NASDAQ: REGN ) halting the Phase 3 trial of its antibody cocktail in patients with severe COVID-19, citing safety issue. Kala Pharmaceuticals Inc. (NASDAQ: KALA ) announced FDA approval for its dry eye disease drug, while Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI ) communicated a delay in the decision for its treatment option for chemotherapy-induced neutropenia, as the FDA could not inspect a plant in South Korea due to COVID-19.
   Eagle Pharmaceuticals’ Presentation at Piper Sandler 32nd Annual Virtual Healthcare Conference Available for Viewing  2020/11/23 11:50:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company’s pre-recorded presentation at the Piper Sandler 32nd Annual Virtual Healthcare Conference is now available for viewing via the link below: https://pipersandler.zoom.us/rec/play/0TlXfXVGZ3QG7IgEE4PyzFEfiG8HyD57XqSaO9Uq1Rsb_J29jmyS2ZvqWskPC1MJPA_AP6kFUMjJQfFd.vyuNfKmJI0FvhIOg It is also available on the Company’s website at www.eagleus.com, under the Inves
   Eagle Pharmaceuticals Inc. (EGRX) Q3 2020 Earnings Call Transcript  2020/11/02 17:30:04 AlphaStreet
Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) Q3 2020 Earnings Call dated Nov. 02, 2020 Corporate Participants: Lisa M. Wilson — Investor Relations – In-Site Communications, Inc. Scott Tarriff — Founder, Chief Executive Officer and Director […]
   Earnings Scheduled For November 2, 2020  2020/11/02 12:55:36 Benzinga
Companies Reporting Before The Bell • Itron (NASDAQ: ITRI ) is likely to report quarterly earnings at $0.25 per share on revenue of $540.01 million. • AMC Networks (NASDAQ: AMCX ) is projected to report quarterly earnings at $1.28 per share on revenue of $606.04 million. • BWX Technologies (NYSE: BWXT ) is likely to report quarterly earnings at $0.68 per share on revenue of $499.24 million. • Clorox (NYSE: CLX ) is projected to report quarterly earnings at $2.32 per share on revenue of $1.75 billion. • Camping World Holdings (NYSE: CWH ) is estimated to report quarterly earnings at $0.96 per share on revenue of $1.51 billion. • Eagle Pharmaceuticals (NASDAQ: EGRX ) is likely to report quarterly earnings at $0.28 per share on revenue of $47.02 million. • Exterran (NYSE: EXTN ) is likely to report quarterly loss at $0.48 per share on revenue of $194.32 million. • FirstEnergy (NYSE: FE ) is likely to report quarterly earnings at $0.76 per share on revenue of $2.94 billion. • MGM Growth Properties (NYSE: MGP ) is expected to report quarterly earnings at $0.
   Eagle Pharmaceuticals Reports Third Quarter 2020 Results  2020/11/02 11:47:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and nine months ended September 30, 2020. Business and Recent Highlights: Received formal notification from FDA granting Priority Review for the Company’s abbreviated new drug application (“ANDA”) filed for vasopressin. A trial date of January 11, 2021 has been set; Added four experienced pharmaceutical industry executives to clinical, form
   The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings  2020/11/01 14:40:39 Benzinga
Biotech stocks continued to sway to the tunes of the broader market in the week ended Oct. 30, which succumbed to geopolitical and macroeconomic concerns. Several big-name pharma companies, including Merck & Co. Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ), reported earnings during the week. The earnings news flow was broadly mixed. Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) was among the biggest decliners, as it halted a late-stage trial of its Duchenne muscular dystrophy drug. On the other hand, Scholar Rock Holding Corp. (NASDAQ: SRRK ) was up about over 175% during the week, reacting to positive mid-stage results for spinal muscular atrophy drug. On the COVID-19 front, Regeneron Pharmaceuticals Inc. said it is (NASDAQ: REGN ) halting the Phase 3 trial of its antibody cocktail in patients with severe COVID-19, citing safety issue. Kala Pharmaceuticals Inc. (NASDAQ: KALA ) announced FDA approval for its dry eye disease drug, while Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI ) communicated a delay in the decision for its treatment option for chemotherapy-induced neutropenia, as the FDA could not inspect a plant in South Korea due to COVID-19.

 関連キーワード  (医薬品 米国株 イ―グル・ファ―マシュ―ティカルズ EGRX Eagle Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)